Individually orientated choice of mucolytic drug for coughing in a child with acute respiratory viral infections

Coughing in acute respiratory infections, regardless of the level of infection: upper or lower respiratory tract is a frequent clinical symptom in childhood. The analysis of the modern literature and the data of the authors’ own researches testify to the fact that the prescription of mucoactive therapy in a complex of therapeutic measures (etiotropic, basic therapy, bronchopulmonary drainage, etc.).) should be differentiated and determined not only by the nature and severity of coughs, separated sputum, but also by individual characteristics of the patient, the severity and course of bronchopulmonary pathology, the age of the child, the presence of adverse environmental factors (in particular, passive smoking), the level of compliance with the patient. The use of combined medications simultaneously influencing various pathogenetic mechanisms of inflammation and coughing becomes a promising direction of mucoactive therapy. One of them is Eucabal® syrup containing liquid extracts of thyme and plantain. Due to the synergy of its components, Eucabal® syrup has an expectorant and anti-inflammatory effect, which is important in the initial period of acute respiratory viral infections (tracheitis, bronchitis tracheobronchitis), especially in dry, painful cough with hard-to-remove sputum. In case of acute respiratory viral infections accompanied by a wet cough with a viscous, difficult to separate sputum, mucolytic agents are shown first of all. One of the modern widely used drugs of this group is acetylcysteine (ESPA-NAC®) in a convenient dosage form.

1. Chuchalin A.G., Abrosimov V.N. Coughing. M.: GEOTAR-Media, 2016, 160. (In Russ).

2. Bilichenko T.N., Chuchalin A.G. Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccine prophylaxis. Therapeutic archive [Terapevticheskiy arkhiv]. 2018;01:22-26. (In Russ).

3. Zaitsev A.A. Coughing: Protusive therapy in focus. RMJ. 20184;26:10-1, 22-25. (In Russ).

4. Mizernitskiy Yu.L. Expectorant and mucolytic agents in therapy of bronchopulmonary diseases in children. Guidance on pharmacotherapy in pediatrics and pediatric surgery (under the editorship of A.D. Tsaregorodtseva, V.A. Tabolina). T.1 Pharmacotherapy in pediatric pulmonology (edited by S.Yu. Kaganova). Moscow: Medpraktika-M, 2002:123-140. (In Russ).

5. Rozinova N.N., Mizernitsky Yu.L. Chronic lung diseases in children. M: Practice, 2011. 234 с.

6. On the state of sanitary-epidemiological well-being of the population in the Russian Federation in 2017: State report. M.: Federal Service for Supervision in the Sphere of Consumer Rights Protection and Human Well-being, 2018. 268 p.

7. Flu and other acute respiratory viral infections in children. Aspects of antiviral therapy. Clinical and Emergency Pediatrics: News, Opinions, Training, 2015. 1. http://pediatr-nmo.geotar.ru/ru/jarticles_ped/8.html?SSr=0901337a1e01ffffffff27c__07df080e010912-40fa. (In Russ).

8. Vikulov G.H. New and returning respiratory viral infections: algorithms of diagnostics and therapy. DMZ. Medical review [Meditsinskoye obozrenie]. 2018;8(I):511. (In Russ).

9. Melnikova I.M., Mizernitsky Yu.L. Expectorant and mucolytic therapy for acute and chronic bronchopulmonary diseases in children. Practical medicine. Pediatrics. [Prakticheskaya meditsina. Pediatriya.]. 2014;9(85):76-82. (In Russ).

10. Melnikova I.M., Udaltsova E.V., Mizernytsky Yu.L. Coughing in children: when and how to treat? Medical Council [Meditsinskiy sovet]. 2017;1:116-120. (In Russ).

11. Mizernitsky Yu.L., Melnikova I.M. Mucolytic and expectorant pharmacotherapy for lung diseases in children. M.: Publishing House «MEDPRAKTIKA-M», 2013, 120 p. (In Russ).

12. Chang A.B., Oppenheimer J.J., Weinberger M., Grant C.C., Rubin B.K., Irwin R.S.; CHEST Expert Cough Panel. Etiologies of Chronic Cough in Pediatric Cohorts: CHEST Guideline and Expert Panel Report. Chest. 2017 Sep;152(3):607-617.

13. Shields M.D., Bush A., Everard M.L., McKenzie S., Primhak R., on behalf of the British Thoracic Society Cough Guideline Group. Recommendations for the assessment and management of cough in children. Thorax. 2008;63(Suppl III): iii 1-15. doi:10.1136/thx.2007.077370.

14. Melnikova I.M., Udaltsova E.V., Mizernitsky Yu. L. Algorithms of differential diagnostics of diseases accompanied by prolonged and chronic cough in children. Pediatrics. Journal named after G.N. Speransky. [Pediatriya. Zhurnal imeni G.N. Speranskogo.] 2018;97(2):8-18. (In Russ).

15. Tatochenko V.K. (ed). Practical pulmonology of childhood (reference book). M., 2000, 268 p. (In Russ).

16. Melnikova I.M., Mizernitsky Yu. L. Combined expectorants of plant origin in pediatric practice. Medical council [Meditsinskiy sovet]. 2018;2:93-97. (In Russ).

17. Belousov Yu. B., Omelyanovsky V. V. Mucolytic and phytotherapeutic agents. Clinical pharmacology of respiratory diseases. M.: « Universum Publishing», 1996, 176 p. (In Russ).

18. Yaroschuk L.B. Herbal medicines in coughing in children: expediency of application and clinical effectiveness. Collection of works. National Institute of Phthisiology and Pulmonology named after F.G. Yanovskiy of the Academy of Medical Sciences of Ukraine. Kiev. 2007: 19-22. (In Russ).

19. Golovkin D.N., Sharova O.V., Kurkin A.V. Possibilities of phytotherapy in the treatment of coughing in children. Fundamental research [Fundamentalniye issledovaniya]. 2014;4:484-492. (In Russ)

20. Mizernitsky Yu. L., Sorokina E.V. Principles of treatment of acute respiratory diseases (ARVI, bronchitis and pneumonia). In book: «Child and medicine» (2nd edition). T.2 Pharmacotherapy in Pediatrics. M., Overlay, 2008: 479-500. (In Russ).

21. Misernytsky Yu.L., Melnikova I.M., Loginevskaya Ya.V., Batozhargalova B.C., Kozlova L.A. Clinical efficiency of combined mucoactive expectorant therapy in children with acute respiratory infections of the lower respiratory tract. The consulting physician [Lechashiy vrach]. 2011;11:107-112. (In Russ).

22. Vysochina I.L., Petrenko L.L., Dityatkovsky V.A., Ivashina V.I., Tokareva N.M. Cough therapy in acute respiratory diseases in children. Child health [Zdorovye rebenka]. 2014;1(52):69-72. (In Russ).

23. Soroka Yu.A. Mucolytic therapy in pediatric practice. Child health [Zdorovye rebenka].2010;1(22):73-78. (In Russ).

24. Mizernitskiy Yu.L., Melnikova I.M. Place of herbal drugs in the therapy of coughing in children. RMJ. 2017;25(5):324-326. (In Russ).

25. Blazhko V.I., Dementieva Ya.V. Cough: modern approaches to diagnosis and treatment. Acute and urgent conditions in the practice of pediatrician. 2012;6(33). URL: https://urgent.com.ua/ruissue-article-446#Kashel-sovremennye-podhody-k-diagnostike-i-lecheniyu (contact date: 08.01.2019). (In Russ).

26. Wienkötter N., Begrow F., Kinzinger U., Schierstedt D., Verspohl E.J. The effect of thyme extract on beta2-receptors and mucociliary clearance. Planta Med. 2007;73(7):629-635.

27. Braga P.C., Dal Sasso M., Culici M., Galastri L., Marceca M.T., Guffanti E.E. Antioxidant potential of thymol determined by chemiluminescence inhibition in human neutrophils and cell-free systems. Pharmacology. 2006;76(2):61-68.

28. Makarova O.A., Zryachkin N.I., Karalskaya Zh.Zh., Zaitseva G.V. Efficiency of new mucolytic syrup with thyme in bronchitis in children. Coll. of thesis: XXI National Congress on respiratory diseases. Ufa. 2011: 109-110. (In Russ).

29. Engelbertz J., Lechtenberg M., Studt L., Hensel A., Verspohl E.J. Bioassay-guided fractionation of a thymol-deprived hydrophilic thyme extract and its antispasmodic effect. J Ethnopharmacol. 2012;141(3):848-853.

30. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem., 2009;9(1):31-59.

31. Seelinger G., Merfort I., Schempp C.M. Antioxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med. 2008; 74(14):1667-1677.

32. Goncharova O.V. Phytotherapy in complex treatment and rehabilitation of children after acute respiratory viral infection. Medical advice [Meditsinskiy sovet]. 2016;1:58-62. (In Russ).

33. Instruction Eucabal. State Register of Medicines http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4ddf2ff1-0a1f-44b0b5e0-4e846558a8ef&t=.(In Russ).

34. Amelina E.L., Anaev E.H., Krasovsky S.A. et al. Mucoactive therapy. Edited by A.G. Chuchalin, A.S. Belevsky. M.: Publishing House «Atmosphere», 2006. 127 p. (In Russ).

35. Geppe N.A., Snegotskaya M.N., Nikitenko A.A. Acetylcysteine in the treatment of coughing in children. Consilium Medicum. Pediatrics. [Consilium Medicum. Pediatriya.] 2007;2:35-40. (In Russ).

36. Mizernitsky Yu.L., Melnikova I.M., Batozhargalova B.C. Place of acetylcysteine in modern mucolytic therapy in children with bronchopulmonary diseases. Practice of pediatrician, October. [Praktika pediatra, oktyabr’] 2013:30-33. (In Russ).

37. Cazzola M., Rogliani P., Calzetta L., Hanania N.A., Matera M.G. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct;14(5):552-563.

38. Zhang Q., Ju Y., Ma Y., Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Medicine (Baltimore). 2018 Nov;97(45):e13087.

39. Santus P., Corsico A., Solidoro P., et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD. 2014;11:705-17.

40. Vukosavljevic B., Murgia X., Schwarzkopf K. et al. Tracing molecular and structural changes upon mucolysis with N-acetyl cysteine in human airway mucus. Int J Pharm. 2017 Nov 30;533(2):373-376.

41. Sadowska A.M., Verbraecken J., Darquennes K., et al. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:425-34.

42. Mahmoud Abd El Hafiz A., Mohammed El Wakeel L., Mohammed El Hady H. et al. High dose N-acetyl cysteine improves inflammatory response and outcome in patients with COPD exacerbations. Egypt J Chest Dis Tubercul. 2013;62:51-7.

43. Maev I.V., Busarova G.A. Mucolytic means in therapy of chronic obstructive pulmonary disease. Consulting physician [Lechashiy vrach]. 2003;1. http://www.lvrach.ru/2003/01/4530016/#insert_041_p1. (In Russ).

44. Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016 Aug;117:190-7.

45. Volgers C., Benedikter B.J., Grauls G.E., Hellebrand P.H.M., Savelkoul P.H.M., Stassen F.R.M. Effects of N-acetyl-L-cysteine on the membrane vesicle release and growth of respiratory pathogens. FEMS Microbiol Lett. 2017 May 1;364(9).

46. Mata M., Sarrion I., Armengot M., Carda C., Martinez I., Melero J.A., Cortijo J. Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLoS One. 2012;7(10):e48037.

47. Zhao T., Liu Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010 May 12;10(1):140.

48. Pintucci J.P., Corno S., Garotta M. Biofilms and infections of the upper respiratory tract. Eur Rev Med Pharmacol Sci. 2010 Aug;14(8):683-690.

49. Knyazheskaya N.P., Bobkov E.V. Modern mucolytic therapy of respiratory diseases. RMJ. 2018;3(1):30-35 (In Russ).

50. Millea P.J. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009 Aug 1;80(3):265-269.

51. Behr J., Demedts M., Buhl R. et al. Lung function in idiopathic pulmonary fibrosis extended analyses of the IFIGENIA trial. Respir Res. 2009 Oct 27;10:101.

52. Homma S., Bando M., Azuma A. et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018 Jul;56(4):268-291.